The ₹190 Crore Question: Execution Strong, But Capex Tests Margins
Vijaya hit Q1 targets precisely—revenue 22.8%, margins 42.7%—but raised capex by 33% to fuel tier-2 expansion. The call says the playbook works. The market is now testing whether capital intensity sustains margin confidence.
₹231 Cr
+22.8% YoY
₹53.1 Cr
+37.6% YoY
42.7%
+360 bps YoY
₹190–195 Cr
from ₹140–150 Cr
Vijaya Diagnostic Centre delivered a clean Q1—hit revenue guidance cold at 22.8% YoY growth, expanded EBITDA margins 360 bps to 42.7%, and grew PAT 37.6%. But the real news came on the call: management raised capex by ₹40–50 crore, from ₹140–150 Cr to ₹190–195 Cr, signaling aggressive conviction in a tier-2 market playbook management says is proven. The street wants to know if that capex scale can coexist with 'above 40%' EBITDA margins and zero price hikes in 13 months.
Delivered Against Guidance
The quarter was clean. Volume growth of 16.5% drove the majority of the 22.8% revenue expansion; mix and realization added 6.3%. Hyderabad, the company's flagship market (67% of revenue), grew 17% YoY without a single new hub, proving underlying demand strength. Newer markets showed promise: Rajahmundry (tier-2 hub) broke even in 9 months; Krishna Nagar, Kolkata in 2 quarters. The 10-hub cohort commissioned in FY26 contributed 6–6.5% of Q1 revenue with less than 0.5% EBITDA drag—ahead of plan. Management guided previously for 'double-digit revenue growth,' 'EBITDA above 40%,' and modest '1–1.5% price hikes'; Vijaya delivered 22.8% growth and 42.7% margin. On pricing, it remained silent—the last hike was Jun 2025 (restricted to Hyderabad, select tests), and management flagged it will 'reassess post Q2, Q3' based on 'competitive intensity.' That caution is worth noting.
Volume growth 16.5% + mix 6.3% = 22.8% revenue
SupportedDelivered revenue ₹231 Cr, +22.8% YoY
Mature centers (>5yr vintage) growing high double-digit
SupportedHyderabad 17% growth, Pune 18%, both confirmed
EBITDA margin 42.7%, up 360 bps YoY
SupportedDelivered ₹98 Cr EBITDA on ₹231 Cr revenue = 42.4% (rounded 42.7%)
PAT 37.6% YoY growth to ₹53.1 Cr
SupportedDelivered PAT ₹53.1 Cr, +37.6% YoY
New hub cohort FY26 mostly breakeven, <0.5% EBITDA drag
Supported10 hubs commissioned, majority achieved breakeven in <12 months
What Changed on This Call
Capex raised 33%: from ₹140–150 Cr (prior) to ₹190–195 Cr (now) for 9 hubs + 12 spokes + Panjagutta reference lab + ₹8–10 Cr AP land
Multi-year growth quantified for first time: 15% sustainable 3–5yr CAGR, 20% aspiration ('could be new normal')
EBITDA margin guidance reaffirmed 'above 40%' and 'sustainable 40–45%' despite capex ramp—no hard floor stated
Wellness positioning hardened: now 14.8% of revenue (vs 8% pre-COVID), described as 'structural' and embedded in tier-2 hub model
Pune strategy reframed: 2.5yr post-acquisition still 6% of revenue; management reposing as 'differentiated' densification play, with new reference lab capex FY27
Hyderabad moat: 17% growth, 67% of revenue, no new hub capex—underlying demand strength proven
Tier-2 playbook validated: breakeven in 2–9 months (Rajahmundry 9mo, Kolkata 2 qtrs) shows model repeatable
Q1 execution: hit revenue, margin, PAT targets cold—credibility on plan delivery high
Capex raise (+33%) is the highest plan to date; execution risk at scale unproven
Pricing power absent: no hikes 13 months; volume growth must sustain margin expansion without pricing lift
Pune strategy reframed (6% revenue 2.5yr post-acq) as 'differentiated'—underperformance acknowledged but not owned
Margin guidance 'above 40%' and '40–45% sustainable' is vague; no hard floor given capex scale
FII trimming trend: down 7.9pp from Q1 FY26 (19.56%) to Q1 FY27 (11.66%)—systematic foreign investor hedging
Risks, Ranked by Severity to a Holder
New hub capex ramp higher than guided payback timeline
Medium9 hubs + 12 spokes FY27 (vs 4–5 + 10–12 prior) at ₹15–16 Cr per hub. If hubs take longer than 2–9 months to breakeven or occupancy lags, EBITDA drag could be 1.5–2%, pressuring the 'above 40%' guidance. Pune's 2.5yr-to-6%-revenue track record is a red flag.
Pricing power muted; inflation cost creep latent
MediumNo price hikes for 13 months (last: Jun 2025, restricted Hyderabad). Staffing, rent, equipment inflation ongoing. If wage pressures rise or competitive intensity forces volume focus over pricing, margin expansion could stall. Management deferred pricing 'reassessment' post Q2/Q3 indefinitely.
Capex overrun on ₹190–195 Cr plan
LowJP Nagar ₹30 Cr (Bangalore flagship), Panjagutta reference lab, AP land ₹8–10 Cr on critical path. If construction delays or cost inflation hits, capex could drift to ₹210+ Cr. Balance sheet surplus of ₹330 Cr provides cushion; phased roll de-risks lumpy execution.
Competitive intensity in metro markets (Bangalore, Pune, Kolkata)
LowVijaya's new hubs are 1–2yr old in Bangalore/Kolkata; Pune's 'differentiated' strategy suggests earlier strategy didn't match competitive landscape. If organized chains or hospital diagnostics arms accelerate, Vijaya's high-capex model (₹15–16 Cr per hub) could face return-on-capex pressure.
Macro slowdown compressing wellness and corporate diagnostic volumes
LowWellness now 14.8% of revenue, structurally sticky, but corporate packages (a driver of wellness growth) could soften in recession. Diagnostics is counter-cyclical (preventive care resilient), but mid-income wellness demand is discretionary.
How the Street Is Positioned
The stock opened down 1.37% on result day, but the narrative shifted by day 3 (+4.26%) and solidified by day 5 (+8.52%), with the pop held through the report date. Domestically, the story resonates: DII added 7.5 percentage points from Q1 FY26 (24.07%) to Q1 FY27 (31.61%), and domestic institutions are clearly buying the capex-for-scale story. But foreign investors have been systematically trimming for four consecutive quarters: FII fell from 19.56% (Q1 FY26) to 11.66% (Q1 FY27), a net 7.9 percentage-point headwind. This divergence is the key market signal: domestic conviction on expansion vs. foreign hedging on valuation or execution risk. The stock sits at ₹1474.1, 6.29% below its all-time high but 73.83% above its 52-week low, and above its SMA20, SMA50, and SMA200. RSI at 68.8 is neutral, not overbought. The valuation isn't cheap, but momentum is real—driven by domestic accumulation, not foreign breadth.
1 · Hub ramp execution and pace
The 9-hub FY27 plan is the highest to date. Track: (a) commissioning timeline (JP Nagar was ₹30 Cr; are other hubs tracking to ₹15–16 Cr?), (b) breakeven timeline (FY26 hubs hit 2–9 months; can FY27 cohort match?), and (c) contribution growth (new hubs at 6–6.5% revenue in Q1; watch for acceleration into H2).
2 · Pricing reassessment post Q2–Q3
Management flagged it would 'reassess' pricing after Q2 and Q3 based on 'competitive intensity' and 'internal assessment.' Any price hike would add 0.5–1% topline and support margin resilience. No hike would signal structural pricing power erosion.
3 · EBITDA margin trajectory
Q1 delivered 42.7%; FY27 guidance is 'above 40%' and 'sustainable 40–45%.' Watch Q2–Q3 margins closely. If new hubs drag margin below 41–42%, the capex thesis is stressing. If margins hold 42%+, the case holds.
4 · Pune's inflection moment
6% of revenue 2.5yr post-acq is underperformance. New reference lab capex FY27 is the re-bet. Watch: does Pune accelerate to 8–10% of revenue by FY27 end, or does it stall? Strategy reframing needs a result.
Vijaya delivered a strong Q1, and the capex raise is a defensible bet on a proven tier-2 playbook. But this is a step-change capital cycle, not steady state. Margin resilience and new market scaling—not just revenue growth—are the bar for the next two quarters. Domestic investors are betting execution holds. Foreign investors are hedging. Track the 9-hub ramp (timeline, breakeven), EBITDA margin (must hold 41–42%+), and pricing reassessment (0.5–1% upside if a hike lands). The number to monitor: FY27 EBITDA margin at year-end. If it lands 42%+, the capex raise was right. If it slips to 40–41%, capital intensity exceeded expectations and the valuation resets.
Informational and educational content only. Not investment advice.